Clinical reviewer: Dr. Sarah Boss, MD

This guide is published by COGNIFUL, part of THE BALANCE GROUP in Mallorca, Spain. It compares selected European care models rather than an independent ranking of luxury residences. The UK and Switzerland are included as European locations, with their own access arrangements to check. Provider inclusion does not establish international eligibility or an available place. [1] [2]

Cannabis use disorder is assessed through the pattern and consequences of use. Difficulty controlling it, unsuccessful attempts to reduce it, craving, and effects on responsibilities or relationships are among the features described by the CDC. The fact that a product is available, familiar, or socially accepted does not settle whether an individual needs help. [3]

Discuss frequency, product type, known strength, route of use, and other substances with the assessing clinician. Include prescribed medication and uncertainty about any product. COGNIFUL’s cannabis pathway considers these details alongside sleep, mood, and everyday functioning. The aim is an accurate picture rather than a simple label such as occasional or regular. [1]

Ask what cannabis has come to do in the person’s daily routine. It may be connected with relaxation, sleep, social contact, distress, or a pattern that has become difficult to change. Those possibilities should be explored rather than assumed. A program should explain how its clinical work will address the individual’s experience.

If cannabis is prescribed, include the original condition and prescriber in the assessment. Concerns about use should be examined alongside the treatment purpose and ongoing medical needs. A residential package should not dictate a change to prescribed care without the responsible professionals’ involvement.

A person does not need to fit a stereotype to benefit from assessment. Continuing to work or manage some responsibilities does not rule out a problem; cannabis use alone does not establish a disorder either. The provider should be able to explain its clinical reasoning and proposed level of care.

The NHS describes drug treatment as dependent on the substances and the person’s circumstances, with different forms and intensities of support. Ask whether the person can engage with outpatient care in the current environment or whether a structured period away is appropriate. A private budget is not, by itself, a clinical reason for residence. [4]

Outpatient work can connect treatment with the situations that occur at home. Residential care creates a different environment and requires a later transition. Ask what the proposed setting adds and how the program will prepare the person for the routines that return afterward. Neither model should be selected solely from a marketing description of comfort.

Frequent cannabis use can be followed by withdrawal symptoms when it stops, including sleep problems, irritability, anxiety, low mood, and appetite changes. Professional support may be useful, and concerning symptoms deserve assessment. These experiences do not automatically establish a need for hospital care or a long residence; the whole clinical picture matters. [5]

Possible psychosis, severe confusion, or an immediate psychiatric safety concern needs prompt medical assessment, with urgent care when safety is at risk. A private residential inquiry should not delay that response. The Royal College of Psychiatrists advises early help for psychosis symptoms, and COGNIFUL’s scope requires a different care setting when acute needs exceed the residence. [5] [6]

Other substances should be assessed separately. A cannabis inquiry may also involve alcohol, sedating medication, or another drug. Do not assume the risks or treatment needs are the same. A provider should state what it can manage and what must happen elsewhere before admission. [6]

These are deliberately different models. A locally organized service may provide appropriate treatment without luxury accommodation, while a private residence may offer a small setting without hospital capabilities. The table should help identify what clinical work and access route apply, not create a hierarchy based on room category.

A Netherlands comparison can test the need for residence

Jellinek describes cannabis treatment through behavioral care with different intensities. For an eligible person, that makes it a useful reference when asking whether treatment can take place while living at home. An overseas visitor should confirm access, language, and the specific location rather than assume the same pathway is open to everyone. [7]

Ask how a local provider chooses intensity and reviews it. A plan that begins with outpatient care may require adjustment if needs change; an initial residential recommendation also deserves review. The point is to understand the clinical process rather than buy a fixed setting without a rationale.

A Swiss comparison requires attention to catchment

The Zurich service’s stated population matters. The official description names adults aged 18–65 and preferably residents of the canton. A person from elsewhere should ask about referral and eligibility, not assume an international self-pay route. A service can be clinically relevant to a comparison without being a realistic admission option for every reader. [8]

If you live in another Swiss canton, ask your existing clinician or relevant local service what pathway is available. An overseas residence should be compared with a viable local option rather than only with a prominent institution whose access has not been established.

UK residents can begin with local assessment

The NHS describes contacting a GP or self-referring to a local drug treatment service. That can help clarify cannabis-related needs and the appropriate intensity before exploring private care abroad. A local assessment can also identify the receiving team for a later transition. [4]

If a UK resident chooses Mallorca, the plan should explain what happens before departure, during the stay, and after returning. COGNIFUL’s Spanish location must remain clear. A guide aimed at UK readers does not mean the program has a UK residence.

Spain can be the destination or the home setting

For a person who lives in Spain, Mallorca may be a domestic residential option with a receiving clinician elsewhere in the country. For another European resident, it is an international stay. The clinical questions overlap, but records, language, medication responsibility, and travel arrangements need to reflect the actual route.

Do not assume that European proximity creates one healthcare system. Establish clinical acceptance, referral requirements, and the relevant professionals at each stage. If another service is needed before residence, ask who makes that arrangement and who confirms readiness for transfer. [9]

WHO guidance identifies cognitive behavioral therapy, motivational enhancement, and family approaches as options for cannabis dependence, with a conditional recommendation and low-quality evidence. The appropriate response is to ask about methods, goals, and review without treating any technique as a guaranteed result. [10]

Ask how the program works with motivation and ambivalence. A person may recognize costs of cannabis use while still feeling it provides something important. The clinical work should make room for that discussion and help develop understandable goals. Family expectations should be considered without replacing the patient’s role in treatment.

Ask what practical skills will be developed. Will sessions examine situations associated with use, decisions during craving, and responses when a plan does not work? A provider should describe what happens in treatment and how the person practices it. This is more informative than an extensive therapy menu without a selected program.

Sleep and mental health need explicit attention when relevant. If cannabis has become linked to bedtime or coping with distress, ask how the underlying concern will be assessed. A comfortable environment may make participation easier, but it does not establish a clinical sleep intervention or resolve every psychiatric symptom.

For co-occurring needs, identify who coordinates the plan. The Royal College of Psychiatrists recommends professional support for mental health concerns related to cannabis. COGNIFUL describes coordinated consideration of co-occurring needs, but the actual clinicians and scope should be agreed rather than presumed. [5] [11]

Ask how progress is reviewed with the person. The goals may concern use, functioning, engagement, and responses to relevant situations, depending on assessment. Attendance alone is not a complete outcome. A useful review should inform what happens next, including adjustment or a different level of care if appropriate.

Questions for a more detailed clinical conversation

These questions avoid assuming that every cannabis problem has the same explanation. One person may have found a previous therapy useful but lost support afterward. Another may never have had a careful assessment of sleep or mental health. The new plan should respond to that history rather than repeat an unexamined package in a different country.

Ask the clinician to explain the connection between each proposed intervention and an agreed goal. This does not mean every session must produce a measurable immediate result. It means the overall approach should be understandable and open to review. A patient should be able to ask why a method is being used and what would lead the team to reconsider it.

COGNIFUL is located in Mallorca and is part of THE BALANCE GROUP. Cannabis addiction is a named treatment pathway, subject to clinical suitability and availability. Ask whether the person’s current symptoms, other substances, and mental health needs fit the residence. Acute medical or psychiatric problems may require another service first; COGNIFUL is not being presented as an acute hospital. [1] [6]

The residence has a maximum of four clients at any time, each with a private suite. Clinical and bodywork sessions are individual. The residence, chef, and personal manager are shared in both programs. Other holistic sessions, excursions, and activities are shared in Premier; every session and activity is individual in Premier Plus. Both program tiers use this format. The small capacity does not establish a staffing ratio, clinical session frequency, or comparative outcome. [2]

COGNIFUL Premier and Premier Plus both include assessment, a personal plan, and continuing-care planning. Plus adds individual therapeutic work, family and transition work, and three months of aftercare. Base-program follow-up is agreed individually. Typical stays are four to twelve weeks, with individual review rather than a cannabis recovery schedule. [12] [13] View program fees

Ask for the specific psychological work and professionals proposed for the admission. THE BALANCE GROUP’s shared team does not mean every clinician participates in every plan. Likewise, WHO’s treatment options are questions to discuss, not proof that each method is offered in every COGNIFUL stay. The schedule and approach should be confirmed for the individual. [14] [15]

The program is self-pay and does not directly bill insurers. Request a written total with duration assumptions, inclusions, and exclusions. Continuing care should be discussed for the country where the person will live, including actual receiving clinicians and appointments. The existence of aftercare does not establish universal European telehealth or cross-border prescribing. [12] [13] [9]

Confirm clinical language for assessment, therapy, family work, and discharge documents. If the home team uses another language, arrange clear communication of essential recommendations. Reception or admissions language alone is not enough to establish the full treatment experience.

Discuss work and family responsibilities during the stay. Ask what the schedule requires and what outside contact can realistically fit. If relatives participate, establish consent and a useful role. They may offer support without becoming responsible for clinical monitoring.

Identify the receiving professional and first follow-up before discharge. Ask who sends records, who reviews medication if relevant, and how to obtain reassessment when symptoms or use change. COGNIFUL’s professional referral route can support this planning, but each actual arrangement must be agreed. [9]

Compare complete costs rather than a weekly rate alone. Include known assessment, external care, travel, and later treatment needs. Ask why proposed durations differ and what progress reviews may change. A clear clinical and financial proposal makes the decision more accountable.

Use the first week back home to test whether the transition is concrete. Which appointments are in the calendar? What will happen during the familiar evening or social situation previously linked to use? Who can be contacted if distress increases? The plan should give the person realistic actions and accessible support, not depend on preserving the residential environment indefinitely.

Clarify privacy through actual arrangements. Ask who receives records, which practical updates can go to relatives or an employer, and how shared residential spaces work. An overseas location does not guarantee anonymity. Clear consent and communication procedures are more useful than an undefined promise of discretion.

Finally, ask what the provider still needs to know before recommending admission. A careful process may identify a missing assessment or the need for another service first. Those boundaries help make the eventual choice more suitable, especially when the person is comparing programs far from established support.

Does cannabis treatment require an inpatient stay?

Not always. Outpatient and more intensive options should be considered according to assessment. Ask why the proposed setting fits the person rather than assuming that residential treatment is automatically best. [4]

Can a European service accept anyone who pays privately?

No. Eligibility and clinical suitability remain separate requirements. The Zurich service, for example, describes a preferred local population and age range. Confirm the actual access route. [8]

Should withdrawal symptoms be ignored because cannabis is familiar?

No. Sleep, mood, irritability, and appetite changes can warrant support. Severe or acute psychiatric symptoms require medical assessment rather than being dismissed as routine discomfort. [5]

How do I explore COGNIFUL?

Request a clinical suitability review, the cannabis-specific proposal, written fees, and a receiving plan in your home country. Provide accurate substance and mental health information before travel is arranged. [9] [12]

1. Cannabis addiction treatment at COGNIFUL — COGNIFUL
2. Life at COGNIFUL in Mallorca — COGNIFUL
3. Understanding your risk for cannabis use disorder — Centers for Disease Control and Prevention
4. Drug addiction: getting help — NHS
5. Cannabis and mental health — Royal College of Psychiatrists
6. Clinical scope, suitability and care coordination — COGNIFUL
7. Cannabis treatment options — Jellinek
8. Addiction disorders and dual diagnoses — Psychiatric University Hospital Zurich
9. Professional referrals — COGNIFUL
10. Psychosocial interventions for cannabis dependence — World Health Organization
11. Co-occurring mental health and addiction needs — COGNIFUL
12. COGNIFUL programs, fees and admissions — COGNIFUL
13. Reintegration and continuing care — COGNIFUL
14. Clinical team and care coordination — COGNIFUL
15. How residential treatment works at COGNIFUL — COGNIFUL

Source information checked October 18, 2026. Confirm current services, eligibility, fees, and availability directly with each provider.